This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eisai Co., Ltd.
Drug Names(s): ZYC101a, E7101
Description: ZYC101a is a novel therapeutic candidate designed to work with the body's own defense system. ZYC101a contains plasmid-DNA–encoding fragments derived from the E6 and E7 proteins of human papillomavirus (HPV) 16 and 18, and is formulated within small biodegradable microparticles. These fragments signal to disease-fighting T cells to attack cervical cells infected by HPV. ZYC101a is designed to treat cervical dysplasia associated with all major oncogenic strains of the virus.
Deal Structure: MGI PHARMA signed a definitive merger agreement, on 9/1/04, under which MGI PHARMA will acquire Zycos for $50 million in cash. This transaction, which has been approved by the boards of directors of both companies, is subject to approval by the stockholders of Zycos. MGI PHARMA and Zycos expect the transaction to close in September 2004.
In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.
Additional information available to subscribers only: